Berman JJ, Datta M, Kajdacsy-Balla A, et al. The tissue microarray data exchange specification: implementation by the Cooperative Prostate Cancer Tissue Resource. BMC Bioinformatics 2004;5:19.
Bolli M, Schultz-Thater E, Zajac P, et al. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer 2005;115:960–966.
Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst. 1999;91:1758–1764.
Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hydridization on tissue microarrays. Cancer Res. 1999;59:803–806.
Bubendorf L, Nocito A, Moch H, et al. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol. 2001;195:72–79 (review article).
Chung GG, Yoon HH, Zerkowski MP, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006;106:1677–1684.
Dell’Anna R, Demichelis F, Barbareschi M, et al. An automated procedure to properly handle digital images in large scale tissue microarray experiments. Comput Methods Programs Biomed. 2005;79:197–208.
Diaz LK, Gupta R, Kidwai N, et al. The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer. J Histochem Cytochem. 2004;52:501–507.
Fowler JM, Ramirez N Cohn DE, et al. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol. 2005;192:1262–1271; discussion 1271–1273.
Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003;101:681–689.
Gulmann C, Loring P, O’Grady A, et al. Miniature tissue microarrays for Hercep Test standardisation and analysis. J Clin Pathol. 2004;57:1229–1231.
Hendriks Y, Franken P, Dierssen JW, et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol. 2003;162:469–477.
Howard BA, Zheng Z, Campa MJ, et al. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004;46:313–323.
Kallioniemi OP, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet. 2001; 10:657–662 (review article).
Kay E, O’Grady A, Morgan JM, et al. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing. J Clin Pathol. 2004;57:1140–1144.
Kettunen E, Nicholson AG, Nagy B, et al. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray Carcinogenesis 2005;26: 17–25.
Kim R, Demichelis F, Tang J, et al. Internet-based Profiler system as integrative framework to support translational research. BMC Bioinformatics 2005;6:304.
Kocher T, Zheng M, Bolli M, et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 2002;100:702–705.
Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4:844–847.
Koynova DK, Tsenova VS, Jankova RS, et al. Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx. J Cancer Res Clin Oncol. 2005;131:199–203.
Kuefer R, Hofer MD, Gschwend JE, et al. Tissue microarrays. High-throughput procedures to verify potential biomarkers. Urologe A. 2004;43:659–667 (review article).
Linke SP, Bremer TM, Herold CD, et al. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res. 2006;12:1175–1183.
Liu CL, Montgomery KD, Natkunam Y, et al. TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod Pathol. 2005;18:1641–1648 (review article).
Liu X, Minin V, Huang Y, et al. Statistical methods for analyzing tissue microarray data. J Biopharm Stat. 2004;14:671–685 (review article).
Lusis EA, Chicoine MR, Perry A. High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol. 2005;73:219–223.
Manley S, Mucci NR, De Marzo AM, et al. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol. 2001;159:837–843 (review article).
Mengel M, Kreipe H, von Wasielewski R. Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. Appl Immunohistochem Mol Morphol. 2003;11:261–268 (review article).
Mirlacher M, Kasper M, Storz M, et al. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol. 2004;17:1414–1420.
Moch H, Kononen T, Kallioniemi OP, et al. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol. 2001; 8:14–20 (review article).
Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999;154:981–986.
Nielsen TO, Hsu FD, O’Connell JX, et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol. 2003; 163:1449–1456.
Nocito A, Bubendorf L, Tinner EM, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol. 2001;194:349–357.
Packeisen J, Korsching E, Herbst H, et al. Demystified tissue microarray technology. Mol Pathol. 2003;56:198–204 (review article).
Rubin MA, Dunn R, Strawderman M, et al. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol. 2002;26:312–319.
Rubin MA, Mucci NR, Figurski J, et al. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol. 2001;32:690–697.
Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 1999;5:1966–1975.
Schraml P, Schwerdtfeger G, Burkhalter F, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol. 2003;163:985–992.
Simon R, Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol. 2002;30:1365–1372 (review article).
Simon R, Sauter G. Tissue microarray (TMA) applications: implications for molecular medicine. Expert Rev Mol Med. 2003;2003;1–12 (review article).
Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol Med. 2005;114:257–268 (review article).
Staller P, Sulitkova J, Lisztwan J, et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307–311.
Struckmann K, Schraml P, Simon R, et al. Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. Cancer Res. 2004;64:1632–1638.
Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001; 159:2249–2256.
Tzankov A, Pehrs AC, Zimpfer A, et al. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol. 2003;56:747–752.
Tzankov A, Zimpfer A, Lugli A, et al. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin’s lymphoma indicates overexpression of cyclin E1. J Pathol 2003;199:201–207.
Varga Z, Theurillat JP, Filonenko, V, et al. Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. Clin Cancer Res.. 2006;12:2745–2751.
Went P, Vasei M, Bubendorf L, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006;94:128–135.